Image

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Recruiting
3 - 18 years of age
Both
Phase N/A

Powered by AI

Overview

To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children

Eligibility

Inclusion Criteria:

1, age 3-18 years old (including boundary value), male and female;

        2. The patient was clinically diagnosed as relapsed/refractory B acute lymphoblastic
        leukemia/lymphoblastic lymphoblastic
        Patients with tumors who meet one of the following conditions:
        • Complete marrow response (MRD>1%) or not achieved after at least 2 courses of
        standardized induction regimen chemotherapy
        Complete response at the molecular level and immunology (characterized by specific
        molecular markers and immunophenotypes prior to treatment)
        Patients, did not turn negative after treatment);
          -  Recurrence during chemotherapy, early recurrence after drug withdrawal (<12 months) or
             late recurrence after complete remission (≥
             12 months) and did not achieve complete remission after 1 course of standard induction
             regimen (MRD>1%);
          -  Recurrence after bone marrow transplantation;
          -  Simple bone marrow, simple extramedullary (testicular leukemia, central nervous system
             leukemia) or combined
        recrudescence
        3. Lansky score ≥60;
        4, the treatment related antigen test result is positive (CD19/CD20/CD22);
        5. The expected survival period from the signing date of the informed consent is more than
        3 months;
        6, HGB≥70g/L (blood transfusion);
        7, liver and kidney function, cardiopulmonary function meet the following requirements:
          1. Creatinine ≤1.5×ULN;
          2. Left ventricular ejection fraction ≥50%;
          3. Blood oxygen saturation >90%;
          4. Total bilirubin ≤1.5×ULN; ALT and AST≤2.5 x ULN.-
             Exclusion Criteria:
               -  1, severe cardiac insufficiency, left ventricular ejection fraction <50%;
                  2, have a history of severe lung function impairment;
                  3. Combined with other advanced malignant tumors;
                  4, combined with serious infection and can not be effectively controlled;
                  5, combined with serious autoimmune disease or congenital immune deficiency;
                  6, active hepatitis (hepatitis B virus deoxyribonucleic acid [HBVDNA] or
                  hepatitis C virus ribonucleic acid [HCVRNA] positive);
                  7, human immunodeficiency virus (HIV) infection or known acquired
                  immunodeficiency syndrome (AIDS), or syphilis infection;
                  8. Have a history of severe allergy to biological products (including
                  antibiotics);
                  9. Patients with allogeneic hematopoietic stem cell transplantation still had
                  acute graft-versus-host response (GvHD) one month after immunosuppressant
                  discontinuation;
                  10, the presence of other serious physical or mental illnesses or abnormalities
                  in laboratory tests that may increase the risk of participating in the study or
                  interfere with the study results, as well as patients deemed unsuitable for
                  participation in the study by the investigator.

Study details

B Lymphocytic Leukemia, B Lymphoblastic Lymphoma

NCT06355739

Zhu Xiaofan

18 April 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.